Jubilant Ingrevia: 2025 update on shares lagging Sensex

Stock underperforms across key time frames

Jubilant Ingrevia’s share performance has trailed the broader market and sector peers across multiple periods, keeping the stock on investors’ watchlists for the wrong reasons. Over the past week, the stock fell 6.5%, compared with a 3.84% decline in the Sensex. The gap widened over a month, with Jubilant Ingrevia down 15.21% versus a 5.61% fall for the benchmark.

The underperformance has persisted year-to-date as well. Jubilant Ingrevia is down 21.17% YTD, while the Sensex is down 7.16% over the same period. Even on a one-year view, the stock delivered a negative return of 8.01% against the Sensex’s gain of 8.39%.

The consistency of the divergence is central to how the market is reading the story: investors appear to be pricing in concerns around growth visibility and profitability, rather than reacting to a single weak quarter.

What the market is focusing on

The stated reasons behind the selling pressure centre on weak sales growth and deterioration in profitability indicators. The narrative in the data is not limited to one reporting period. The company’s longer-term growth has been described as lacklustre, while quarterly profit measures have also disappointed relative to recent run-rates.

From a trading perspective, the stock has also been flagged as being near its 52-week low and trading below key moving averages, which tends to keep risk appetite muted in the near term.

Long-term fundamentals: five-year sales and operating profit trend

Over the last five years, Jubilant Ingrevia’s net sales have shrunk at an annualised rate of 0.45%. More importantly for sentiment, operating profit has contracted at a much sharper annualised rate of 13.67% over the same period.

That combination typically raises two questions in the market: whether the company is facing structural pricing pressure, and whether its cost base and mix can support margins through cycles. In this case, the five-year operating profit decline is a key reason investors are closely tracking execution and segment recovery signals.

Recent quarterly pressure: PBT (less other income) and PAT fall

More recent performance indicators have also been weak in parts. Profit before tax excluding other income (PBT less OI) fell 21.1% to ₹69.03 crore compared with the average of the previous four quarters. Net profit after tax (PAT) declined 21.9% to ₹56.25 crore on the same comparison.

Such a drop versus the recent average can unsettle expectations, especially when the stock is already underperforming the market. It also increases the focus on whether the decline is cyclical or tied to ongoing segment-specific headwinds.

Working capital signal: debtors turnover at 5.56x

Operational efficiency has also been highlighted as a concern. The company’s debtors turnover ratio stood at 5.56 times for the half-year period, indicating slower collection of receivables.

For a manufacturing business, receivables discipline is an important working-capital lever. When collections slow, liquidity can tighten even if reported profits appear stable, which is why this metric can influence investor risk perception.

Share price snapshots: two reference points from reported updates

The stock has seen sharp moves around results and broader sentiment swings. In one share price update, Jubilant Ingrevia was reported down 1.49% from its previous close of ₹666.35, last trading at ₹656.45.

In a separate results-linked market update for Q4 FY24, shares were reported to have closed 2.16% lower at ₹508.45 on the NSE, while the benchmark Nifty 50 rose 0.54% that day. Both data points underline that negative reactions have often been company-specific rather than purely market-driven.

Financial snapshot: reported revenue, operating profit, PBT and net profit

The article data also provides a set of quarterly financial numbers showing mixed movement quarter-on-quarter.

• Revenue: ₹1,037.95 crore, down 1.27% QoQ from ₹1,051.26 crore, and up 1.33% YoY.
• Operating profit: ₹23.91 crore, up 7.22% QoQ from ₹22.30 crore.
• Profit before tax: ₹99.77 crore, down 1.97% QoQ from ₹101.78 crore.
• Net profit: ₹75.10 crore, up 1.42% QoQ from ₹74.05 crore, with a 54.08% YoY increase.

This mix can be difficult for the market to price cleanly: QoQ revenue softness alongside a QoQ operating profit rise suggests cost or mix effects, while PBT drift and strong YoY net profit growth can coexist due to base effects and income line movements.

Q4 FY24 results: profit decline and margin pressure

A separate set of reported Q4 FY24 consolidated highlights showed a clear slowdown on a year-on-year basis. Net profit was reported at ₹29.25 crore in the quarter ended March versus ₹52.31 crore a year earlier, and below a Bloomberg-tracked estimate of ₹48.25 crore.

Other Q4 FY24 highlights (YoY) included:

• Revenue down 6.16% to ₹1,074.44 crore (from ₹1,144.98 crore), compared with a Bloomberg estimate of ₹1,030.65 crore.
• EBITDA down 10.5% to ₹91.24 crore (from ₹102.05 crore), versus a Bloomberg estimate of ₹97.20 crore.
• EBITDA margin at 8.49% (from 8.9%), versus a Bloomberg estimate of 9.4%.

Reuters also reported an almost 24% slump in fourth-quarter profit, citing lower chemical prices and sustained challenges in the supplements business, and noted EBITDA margin shrinking to 9.7% from 11.7% a year earlier.

Segment and demand factors: agrochemicals, niacinamide, acetyls

Management commentary referenced muted agrochemical demand impacting earnings and suggested weakness could continue in the near term, with a recovery expected only in the second half of FY24. Another pressure point cited was low price realisations in a segment linked to acetic anhydride.

Reuters noted overall revenue weakness due to lower prices of acetic acid and sustained headwinds in the niacinamide business. It also said the nutrition and health solution business contracted about 25%, and that chemical intermediates revenue dropped as feedstock prices fell.

In a separate Q4 FY25-focused note included in the article data, the chemical intermediates segment was cited as facing a 14% YoY revenue drop, while specialty chemicals and nutrition and health solutions posted YoY revenue growth of 2% and 15%, respectively, helping overall EBITDAM improve by 90 basis points. The same note said niacinamide demand remained steady with stable prices in Q4 FY25, while low ethyl acetate prices affected margins and acetyls volumes were impacted by subdued paracetamol end-use demand.

Key numbers at a glance

Market impact and what investors are watching

The market impact is visible in both relative returns and reactions around results. Underperformance versus the Sensex across one week, one month, YTD and one year suggests that investors are not treating the weakness as a short-lived market move.

What stands out is the combination of weak multi-year operating profit trends, quarterly profit contractions (on some measures), and business headwinds tied to chemicals pricing and nutrition-related challenges. At the same time, the article data also points to positives, including references to a strong balance sheet and attractive valuation metrics, though those were not enough to offset weak sentiment.

The company also declared a final dividend of ₹2.50 per share, according to the Reuters report. Separately, management commentary referenced additional capex of ₹1,150 crore and a peak revenue potential of ₹2,600 crore linked to that investment plan.

Conclusion

Jubilant Ingrevia’s share price weakness, as presented in the article data, reflects investor focus on slow sales growth, operating profit compression over five years, and a run of disappointing quarterly profit signals. The stock’s continued underperformance versus the Sensex adds to the caution, even as some quarterly metrics show improvement and management has outlined capex and longer-term potential. The next key checkpoints are ongoing demand and pricing conditions across chemicals and nutrition, and whether profitability stabilises in upcoming quarters.